Dr. Tam is a Clinical Associate Professor at the University of Calgary and a staff medical oncologist at the Tom Baker Cancer Centre who specializes in the treatment of gastrointestinal malignancies. Dr. Tam completed his medical training at the University of Ottawa, McMaster University and University of Toronto. His academic interests include hepatobiliary cancer, health services research and oncology education. Dr. Tam has been the local principal investigator for a number of phase II and III hepatobiliary clinical trials and currently chairs the CHORD Consortium Canadian Hepatocellular Carcinoma Database.
Tam, Vincent
Medical Oncology
Clinical Associate Professor
MD, BSc(Hon), FRCPC
Biography
Area of Focus
Summary of Research
Key Publications:
- Amaro CP, Tam VC. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second-line and beyond. Current Oncology. 2020 Nov 27(Suppl 3):S173-S180.
- Alghamdi MA, Amaro CP, Lee-Ying R, Sim HW, Samwi S, Chan KK, Knox JJ, Ko YJ, Swiha M, Batuyong E, Romagnino A, Cheung WY, Tam VC. Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multi-center Database. Cancer Medicine. 2020 Jul;9(14):4918-4928.
- Yip SM, Meyers DE, Sisler J, Wycliffe-Jones K, Kucharski E, Elser C, Temple-Oberle C, Spadafora S, Ingledew PA, Giuliani M, Kuruvilla S, Sumar N, Tam VC. Oncology Education for Family Medicine Residents: A National Needs Assessment Survey. BMC Medical Education. 2020 Aug 27;20(1):283.
- Tam VC, Ingledew PA, Berry S, Verma S, Giuliani ME. Developing Canadian Oncology Goals and Objectives for Medical Students: A National Delphi Study. CMAJ Open; 4(3): e359-64. 2016.
- Tam VC, Tannock IF, Massey C, Rauw J, Krzyzanowska MK. Compendium of unpublished phase III trials in oncology: Characteristics and impact on clinical practice. Journal of Clinical Oncology; 29(23):3133-9. 2011.
- Tam VC, Hotte SJ. Consistency of phase III clinical trial abstracts presented at an annual meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications. Journal of Clinical Oncology; 26(13):2205-11. 2008.
Area Of Focus
Summary Of Research
Key Publications:
- Amaro CP, Tam VC. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second-line and beyond. Current Oncology. 2020 Nov 27(Suppl 3):S173-S180.
- Alghamdi MA, Amaro CP, Lee-Ying R, Sim HW, Samwi S, Chan KK, Knox JJ, Ko YJ, Swiha M, Batuyong E, Romagnino A, Cheung WY, Tam VC. Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multi-center Database. Cancer Medicine. 2020 Jul;9(14):4918-4928.
- Yip SM, Meyers DE, Sisler J, Wycliffe-Jones K, Kucharski E, Elser C, Temple-Oberle C, Spadafora S, Ingledew PA, Giuliani M, Kuruvilla S, Sumar N, Tam VC. Oncology Education for Family Medicine Residents: A National Needs Assessment Survey. BMC Medical Education. 2020 Aug 27;20(1):283.
- Tam VC, Ingledew PA, Berry S, Verma S, Giuliani ME. Developing Canadian Oncology Goals and Objectives for Medical Students: A National Delphi Study. CMAJ Open; 4(3): e359-64. 2016.
- Tam VC, Tannock IF, Massey C, Rauw J, Krzyzanowska MK. Compendium of unpublished phase III trials in oncology: Characteristics and impact on clinical practice. Journal of Clinical Oncology; 29(23):3133-9. 2011.
- Tam VC, Hotte SJ. Consistency of phase III clinical trial abstracts presented at an annual meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications. Journal of Clinical Oncology; 26(13):2205-11. 2008.